VRTX

Vertex Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

459.810

-3.46(-0.747%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

467.000

Open

467.000

VWAP

462.41

Vol

975.15K

Mkt Cap

118.08B

Low

458.140

Amount

450.92M

EV/EBITDA(TTM)

25.38

Total Shares

258.05M

111.99B

EV/OCF(TTM)

P/S(TTM)

10.73

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

3.22B

+10.56%

4.981

+25.14%

3.05B

+9.85%

4.596

+4.93%

2.91B

+9.95%

4.277

-133.33%

Estimates Revision

The market is revising Downward the revenue expectations for Vertex Pharmaceuticals Incorporated (VRTX) for FY2025, with the revenue forecasts being adjusted by -0.4% over the past three months. During the same period, the stock price has changed by -3.71%.

Revenue Estimates for FY2025

Revise Downward

-0.4%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.22%

In Past 3 Month

Stock Price

Go Down

-3.71%

In Past 3 Month

26 Analyst Rating

11.74% Upside

Wall Street analysts forecast VRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRTX is 513.80 USD with a low forecast of 420.00 USD and a high forecast of 621.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

13 Hold

0 Sell

Moderate Buy

11.74% Upside

Current: 459.810

Low

420.00

Averages

513.80

High

621.00

11.74% Upside

Current: 459.810

Low

420.00

Averages

513.80

High

621.00

JPMorgan

NULL -> Overweight

maintain

$515 -> $517

2025-07-14

Reason

JPMorgan

Price Target

$515 -> $517

2025-07-14

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Vertex Pharmaceuticals to $517 from $515 and keeps an Overweight rating on the shares. The firm adjusted the company's model ahead of the Q2 report.

RBC Capital

Brian Abrahams

Sector Perform

downgrade

$423 -> $420

2025-06-18

Reason

RBC Capital

Brian Abrahams

Price Target

$423 -> $420

2025-06-18

downgrade

Sector Perform

Reason

RBC Capital analyst Brian Abrahams lowered the firm's price target on Vertex Pharmaceuticals to $420 from $423 and keeps a Sector Perform rating on the shares. With recent management commentary suggesting that the switch to next-gen CF, cystic fibrosis, cocktail Alyftrek from Trikafta - by far the company's largest potential patient pool- - has been gradual, the firm has performed a sensitivity analysis on the potential impact to revenue, margins, earnings, and valuation should market conversion and Alyftrek's uptake ultimately be lower than expected, the analyst tells investors in a research note. RBC concluded that a bearish launch scenario vs. consensus would negatively impact out-year operating margins by about 2% and fair value by $14.

Erste Group

Buy

Hold

downgrade

2025-05-23

Reason

Erste Group

Price Target

2025-05-23

downgrade

Buy

Hold

Reason

Erste Group downgraded Vertex Pharmaceuticals to Hold from Buy. The company's ratio of inventories to sales has reached its highest level in the last 10 years, which is currently having a negative impact, the analyst tells investors in a research note. The firm says Vertex's ratio of receivables to sales is also at a very high level.

Cantor Fitzgerald

Carter Gould

Buy

Initiates

$535

2025-04-22

Reason

Cantor Fitzgerald

Carter Gould

Price Target

$535

2025-04-22

Initiates

Buy

Reason

Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals with an Overweight rating and $535 price target.

RBC Capital

Brian Abrahams

Hold

Maintains

$408 → $420

2025-04-01

Reason

RBC Capital

Brian Abrahams

Price Target

$408 → $420

2025-04-01

Maintains

Hold

Reason

B of A Securities

Ying Huang

Strong Buy

Maintains

$555 → $567

2025-03-31

Reason

B of A Securities

Ying Huang

Price Target

$555 → $567

2025-03-31

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Vertex Pharmaceuticals Inc (VRTX.O) is 24.39, compared to its 5-year average forward P/E of 186.74. For a more detailed relative valuation and DCF analysis to assess Vertex Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

186.74

Current PE

24.39

Overvalued PE

780.54

Undervalued PE

-407.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

22.46

Current EV/EBITDA

17.97

Overvalued EV/EBITDA

46.59

Undervalued EV/EBITDA

-1.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

8.79

Current PS

9.60

Overvalued PS

10.36

Undervalued PS

7.22

Financials

Annual

Quarterly

FY2025Q1

YoY :

+2.96%

2.77B

Total Revenue

FY2025Q1

YoY :

-15.22%

1.03B

Operating Profit

FY2025Q1

YoY :

-41.22%

646.30M

Net Income after Tax

FY2025Q1

YoY :

-40.86%

2.49

EPS - Diluted

FY2025Q1

YoY :

-26.46%

778.20M

Free Cash Flow

FY2025Q1

YoY :

-0.42%

86.90

Gross Profit Margin - %

FY2025Q1

YoY :

-133.17%

-11.33

FCF Margin - %

FY2025Q1

YoY :

-42.92%

23.33

Net Margin - %

FY2025Q1

YoY :

-124.89%

-5.98

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

224.4K

USD

3-6

Months

14.0M

USD

6-9

Months

0.0

USD

0-12

Months

3.3M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 149.17% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

319.8K

Volume

6-9

Months

128.3K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

209.2K

Volume

Months

6-9

1.4M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

8.0K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

65.0K

USD

Months

6-9

8.0K

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

224.4K

USD

3-6

Months

14.0M

USD

6-9

Months

0.0

USD

0-12

Months

3.3M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

VRTX News & Events

Events Timeline

2025-07-03 (ET)

2025-07-03

09:43:14

Vertex Pharmaceuticals presents long-term data on CASGEVY

2025-07-01 (ET)

2025-07-01

07:41:44

Vertex Pharmaceuticals announces EC approval for Alyftrek for CF treatment

2025-06-23 (ET)

2025-06-23

05:04:47

Vertex, Ono announce license agreement for povetacicept in Japan and South Korea

News

2.0

07-16NASDAQ.COM

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors

7.5

07-15SeekingAlpha

Vertex secures NHS England reimbursement deal for Alyftrek cystic fibrosis treatment

4.0

07-14Benzinga

JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $517

People Also Watch

UPS

United Parcel Service Inc

Bristol-Myers Squibb Co

FAQ

What is Vertex Pharmaceuticals Inc (VRTX) stock price today?

The current price of VRTX is 459.81 USD — it has decreased -0.75 % in the last trading day.

VRTX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

VRTX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Vertex Pharmaceuticals Inc (VRTX) stock price today?

What is Vertex Pharmaceuticals Inc (VRTX)'s business?

What is the price predicton of VRTX Stock?

What is Vertex Pharmaceuticals Inc (VRTX)'s revenue for the last quarter?

What is Vertex Pharmaceuticals Inc (VRTX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Vertex Pharmaceuticals Inc (VRTX)'s fundamentals?

How many employees does Vertex Pharmaceuticals Inc (VRTX). have?

What is Vertex Pharmaceuticals Inc (VRTX) market cap?